Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT02503332) enrolled 246 people in total across four groups. Participants received either pegcetacoplan (the treatment being studied) or a sham procedure (a dummy injection with no active medicine), and each was given either once a month or once every other month. The trial was primarily measuring changes in the size of geographic atrophy (GA) — a form of damage to the back of the eye — over 12 months, as well as tracking unwanted events that occurred during the study. Of the 246 people who started, 181 completed the trial. The reported data shows that when measuring the growth of the damaged area in the eye over 12 months, the monthly pegcetacoplan group showed a change of 0.26 mm (on a transformed scale used to handle the shape of the data), the every-other-month pegcetacoplan group showed 0.28 mm, and the combined sham group showed 0.35 mm. When measured as the actual area (untransformed), the reported changes were 1.49 mm², 1.69 mm², and 2.12 mm² respectively. For vision measured by a standard letter-reading chart, all groups showed a decline in score from where they started: the monthly pegcetacoplan group lost an average of 3.31 letters, the every-other-month group lost 5.78 letters, and the sham group lost 4.36 letters. For low-light vision, the monthly group lost 2.73 letters, the every-other-month group lost 3.21 letters, and the sham group lost 0.55 letters. Regarding unwanted events in the study eye, 65 participants in the monthly pegcetacoplan group, 47 in the every-other-month group, and 42 in the sham group reported at least one such event; events considered possibly or probably related to the study drug were reported in 21, 11, and 0 participants respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Macular Degeneration Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are male or female, aged 50 or older
- Your vision in the study eye is at least 20/320 (you can read some letters on a special eye chart, even if not perfectly)
- You have been diagnosed with geographic atrophy (GA) of the macula caused by age-related macular degeneration (AMD), confirmed by a specialist reading center within 14 days before joining the study
- The area of GA in your eye falls within a specific size range — not too small and not too large — as measured by a special eye imaging test (confirm with trial site)
- If you have more than one patch of GA, at least one patch must be above a minimum size (confirm with trial site)
- The GA area can be fully seen and photographed in eye imaging
- The GA area can be measured separately from any related damage near the optic nerve
- A specific pattern of change is visible around the edges of the GA on imaging (confirm with trial site)
- Women who cannot become pregnant, OR women who could become pregnant but have a negative pregnancy test and agree to use approved contraception throughout the study
- Men with female partners who could become pregnant must agree to use approved contraception and not donate sperm during the study
- You are willing and able to give your informed consent to participate
Who may not be able to join:
- Your GA is caused by something other than AMD, such as Stargardt disease or damage from certain medications
- You have a high level of short-sightedness (strong prescription glasses/lenses for distance, over 6 diopters) or a longer-than-normal eye length
- You have or have had the "wet" form of AMD, including any signs of abnormal blood vessel growth in the retina
- You have a retinal disease other than AMD (some minor, harmless conditions of the eye may still be acceptable — confirm with trial site)
- You have a condition such as an advanced cataract or corneal problem that makes it hard to examine your eye properly
- Your eye cannot be adequately photographed or imaged for any reason
- You have had eye surgery (including lens replacement) within the 3 months before joining the study
- You have no natural lens in your eye, or the back part of the lens capsule is missing or damaged (some exceptions may apply — confirm with trial site)
- You have an eye condition that is likely to need surgery during the study period
- There is any reason you cannot receive an injection into the eye, including a current eye or surrounding area infection
- You have a history of eye inflammation (uveitis) or a serious eye infection (endophthalmitis)
- You have ever had an injection directly into the eye at any time in the past
- You have taken part in another clinical trial or used an experimental treatment for AMD or any other experimental drug recently (within approximately 6 weeks or longer before starting)
- You have medical or mental health conditions that, in the doctor's opinion, would make it difficult to attend regular appointments or make participation unsafe
- Any abnormal blood or urine test results that the doctor considers significant enough to make participation unsuitable
- You have an allergy to fluorescein (a dye used in eye imaging)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
9 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Least Square (LS) Mean Change From Baseline in Square Root GA Lesion Size in the Study Eye at Month 12; Number of Subjects With Treatment Emergent Adverse Events (TEAEs) in the Study Eye, Including by Severity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.